Endocrine and Metabolic Science (Nov 2020)
Circulating resistin levels in relation with insulin resistance, inflammatory and endothelial dysfunction markers in patients with type 2 diabetes and impaired fasting glucose
Abstract
Background: Resistin is an adipose tissue secreted protein link with the mechanism involved in the pathophysiology of insulin resistance. Aim of the work: This study aims to investigate the potential role of resistin in insulin resistance in relation with inflammatory markers and endothelial dysfunction markers in impaired fasting glucose (IFG) and type 2 diabetes (T2D). Patients and Methods: This pilot study assess the relation of resistin with insulin resistance (HOMA-IR), adipokines (adiponectin, leptin), inflammatory markers [tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin-6 (IL-6)] and endothelial dysfunction markers [vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1)] cross-sectionally using serum samples obtained from 64 participants; controls (n=29), IFG (n=20) and T2D (n=15). The levels of biomarker were measured by using Randox Evidence biochip analyzer. Statistical analyses were performed by SPSS 21.0 software. Results: Resistin levels in IFG and T2D groups were higher compared to control group. A positive correlation was detected between serum resistin levels with HOMA-IR (p= 0.02), inflammatory markers; TNF-α (p=<0.001), IL-6 (p=0.007) and endothelial dysfunction marker; VCAM-1 (p=0.02) in T2D group. In IFG group, resistin showed a significant positive correlation with IL-6 (p= 0.03). Conclusion: The present study demonstrates the involvement of inflammation and endothelial dysfunction in relation with resistin linked insulin resistance in T2D. The promising insulin resistance biomarker-resistin- among people at high risk to develop type 2 diabetes mellitus and add significant contribution to this highly prevalent population .
